Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MEVPRO-1 in abiraterone-pretreated metastatic castration-resistant prostate cancer
jRCT2051240128Phase 3Active, not recruiting
- Sponsor
- Pfizer
- Start
- Oct 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial in metastatic castration-resistant prostate cancer (mCRPC) comparing Mevrometostat + enzalutamide, Enzalutamide and Docetaxel (3 arms). Primary endpoint: Radiographic progression-free survival. Started Oct 2024; status: active, not recruiting.
02
Drugs
mevrometostatenzalutamidedocetaxel
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on jRCT2051240128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240128.